The post Gif etf launches with COIN STRC exposure, weekly dividends appeared on BitcoinEthereumNews.com. Investors seeking option-based income now have a new wayThe post Gif etf launches with COIN STRC exposure, weekly dividends appeared on BitcoinEthereumNews.com. Investors seeking option-based income now have a new way

Gif etf launches with COIN STRC exposure, weekly dividends

For feedback or concerns regarding this content, please contact us at [email protected]

Investors seeking option-based income now have a new way to access it after the launch of the gif etf on a major US exchange.

REX Shares introduces an income-focused options ETF

REX Shares, a US asset manager, has introduced a new exchange-traded fund trading under ticker GIF. The vehicle packages nine leveraged single-stock ETF strategies into one portfolio designed to deliver weekly dividend distributions to shareholders.

The fund holds equal-weight positions in nine existing REX single-stock ETFs. Each component ETF targets roughly 1.25x leverage to its underlying equity while also writing covered call options to generate premium income that is subsequently paid out to investors.

A covered call strategy involves selling call options against shares already owned in the portfolio. In return, option buyers pay an upfront premium, which creates current income for the fund. However, this approach also caps upside if the underlying stock rallies significantly beyond the option strike price.

Portfolio composition and trading venue

The GIF fund began trading on Cboe Global Markets this week. Moreover, the equal-weight basket spans nine prominent equities: Nvidia, Tesla, Strategy, Coinbase, Robinhood, Palantir, CoreWeave, Eli Lilly, and Walmart.

Coinbase and Strategy provide the ETF’s direct exposure to cryptocurrency-related companies. That said, the remaining holdings extend into artificial intelligence, pharmaceuticals, consumer retail, and broader technology, creating a diversified sector mix despite the single-stock focus.

Strategy’s role as a major Bitcoin proxy

Strategy, formerly known as MicroStrategy, has become one of the most visible corporate holders of Bitcoin. The company currently controls 717,722 BTC, equal to about 3.4% of the cryptocurrency’s fixed maximum supply of 21 million coins.

Despite that substantial Bitcoin position, Strategy’s share price has come under pressure. According to Yahoo Finance data, the stock has dropped more than 60% over the last six months and roughly 50% during the past year. Moreover, a recent Goldman Sachs analysis shows it is the most heavily shorted large-cap US stock when measured by short interest as a share of market capitalization.

This elevated short positioning, combined with its large Bitcoin trove, has helped make Strategy a focal point for investors tracking the gif etf and other vehicles with exposure to its equity.

New Strategy-linked products in Europe

The GIF launch in the United States coincided with renewed activity around Strategy-related securities in Europe. On Wednesday, 21Shares introduced a new exchange-traded product (ETP) offering European investors access to STRC, Strategy’s variable-rate perpetual preferred equity.

The 21Shares Strategy Yield ETP began trading on Euronext Amsterdam under ticker STRC NA on Thursday. Strategy describes STRC as a digital credit instrument structured to pay an annual dividend of 11.25%, adding an income-oriented layer to its capital structure.

This preferred instrument is directly linked to Strategy’s Bitcoin reserves and forms part of the company’s broader strategy to develop fixed-income products backed by its BTC treasury. However, detailed risk metrics and long-term performance characteristics will depend on both Bitcoin price behavior and corporate policy decisions.

Also on Wednesday, Prevalon Energy and Anchorage Digital disclosed that they had allocated portions of their corporate balance sheets to STRC. Neither firm revealed exact investment amounts, underscoring the early-stage nature of this market segment.

How the GIF ETF generates and pays income

The GIF portfolio’s revenue stems from covered call option premiums collected by each of the nine underlying single-stock funds. Moreover, every constituent ETF is structured to pass through this income to shareholders via a weekly distribution schedule, making timing a key feature of the product.

The targeted 1.25x leverage means the fund can amplify both gains and losses relative to direct equity ownership. Investors accept reduced potential upside from option writing in exchange for more regular premium-based cash flows, which may appeal to income-focused traders comfortable with elevated volatility.

REX Shares has not yet released a formal yield forecast for GIF. That said, weekly payout levels will vary as they depend on market volatility, option pricing, and the performance of each underlying stock, rather than on a fixed coupon.

In summary, GIF offers a concentrated basket of leveraged, option-writing single-stock exposures with weekly income distributions, while parallel moves in Europe highlight growing demand for Strategy-linked yield products tied to sizable Bitcoin holdings.

Source: https://en.cryptonomist.ch/2026/02/27/gif-etf-launch-us/

Market Opportunity
REVOX Logo
REVOX Price(REX)
$0.0000982
$0.0000982$0.0000982
-4.19%
USD
REVOX (REX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09